TY - JOUR
T1 - Feasibility of Wearable-Based Remote Monitoring in Patients during Intensive Treatment for Aggressive Hematologic Malignancies
AU - Jacobsen, Malte
AU - Rottmann, Pauline
AU - Dembek, Till A.
AU - Gerke, Anna L.
AU - Gholamipoor, Rahil
AU - Blum, Christopher
AU - Hartmann, Niels Ulrik
AU - Verket, Marlo
AU - Kaivers, Jennifer
AU - Jäger, Paul
AU - Baermann, Ben Niklas
AU - Heinemann, Lutz
AU - Marx, Nikolaus
AU - Müller-Wieland, Dirk
AU - Kollmann, Markus
AU - Seyfarth, Melchior
AU - Kobbe, Guido
N1 - Publisher Copyright:
© 2022 American Society of Clinical Oncology.
PY - 2022
Y1 - 2022
N2 - PURPOSE: Intensive treatment protocols for aggressive hematologic malignancies harbor a high risk of serious clinical complications, such as infections. Current techniques of monitoring vital signs to detect such complications are cumbersome and often fail to diagnose them early. Continuousmonitoring of vital signs and physical activity bymeans of an upper arm medical wearable allowing 24/7 streaming of such parameters may be a promising alternative. METHODS: This single-arm, single-center observational trial evaluated symptom-related patient-reported outcomes and feasibility of a wearable-based remote patient monitoring. All wearable data were reviewed retrospectively and were not available to the patient or clinical staff. A total of 79 patients (54 inpatients and 25 outpatients) participated and received standard-of-care treatment for a hematologic malignancy. In addition, the wearable was continuously worn and self-managed by the patient to record multiple parameters such as heart rate, oxygen saturation, and physical activity. RESULTS: Fifty-one patients (94.4%) in the inpatient cohort and 16 (64.0%) in the outpatient cohort reported gastrointestinal symptoms (diarrhea, nausea, and emesis), pain, dyspnea, or shivering in at least one visit. With the wearable, vital signs and physical activity were recorded for a total of 1,304.8 days. Recordings accounted for 78.0% (63.0-88.5; median [interquartile range]) of the potential recording time for the inpatient cohort and 84.6% (76.3-90.2) for the outpatient cohort. Adherence to the wearable was comparable in both cohorts, but decreased moderately over time during the trial. CONCLUSION: A high adherence to the wearable was observed in patients on intensive treatment protocols for a hematologic malignancy who experience high symptom burden. Remote patient monitoring of vital signs and physical activity was demonstrated to be feasible and of primarily sufficient quality.
AB - PURPOSE: Intensive treatment protocols for aggressive hematologic malignancies harbor a high risk of serious clinical complications, such as infections. Current techniques of monitoring vital signs to detect such complications are cumbersome and often fail to diagnose them early. Continuousmonitoring of vital signs and physical activity bymeans of an upper arm medical wearable allowing 24/7 streaming of such parameters may be a promising alternative. METHODS: This single-arm, single-center observational trial evaluated symptom-related patient-reported outcomes and feasibility of a wearable-based remote patient monitoring. All wearable data were reviewed retrospectively and were not available to the patient or clinical staff. A total of 79 patients (54 inpatients and 25 outpatients) participated and received standard-of-care treatment for a hematologic malignancy. In addition, the wearable was continuously worn and self-managed by the patient to record multiple parameters such as heart rate, oxygen saturation, and physical activity. RESULTS: Fifty-one patients (94.4%) in the inpatient cohort and 16 (64.0%) in the outpatient cohort reported gastrointestinal symptoms (diarrhea, nausea, and emesis), pain, dyspnea, or shivering in at least one visit. With the wearable, vital signs and physical activity were recorded for a total of 1,304.8 days. Recordings accounted for 78.0% (63.0-88.5; median [interquartile range]) of the potential recording time for the inpatient cohort and 84.6% (76.3-90.2) for the outpatient cohort. Adherence to the wearable was comparable in both cohorts, but decreased moderately over time during the trial. CONCLUSION: A high adherence to the wearable was observed in patients on intensive treatment protocols for a hematologic malignancy who experience high symptom burden. Remote patient monitoring of vital signs and physical activity was demonstrated to be feasible and of primarily sufficient quality.
UR - http://www.scopus.com/inward/record.url?scp=85123462048&partnerID=8YFLogxK
U2 - 10.1200/CCI.21.00126
DO - 10.1200/CCI.21.00126
M3 - Article
C2 - 35025669
AN - SCOPUS:85123462048
SN - 2473-4276
VL - 6
JO - JCO Clinical Cancer Informatics
JF - JCO Clinical Cancer Informatics
M1 - e2100126
ER -
